Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY518674 for Blood Pressure Lowering in Mild Essential Hypertension
2005-004966-17Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ly518674 in essential hypertension (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in mean 24-hour ambulatory systolic blood pressure. Started Jun 2006; status: terminated.
02
Drugs
ly518674
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2005-004966-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004966-17.